Yu et al. found that SRPX2 targets the FAK/AKT pathway in hepatocellular carcinoma (HCC) to increase the mobility of HCC cells [34], and SRPX2 promotes EMT in small cell lung cancer [14]. Here, PTK2 is linked to hepatocellular carcinoma.